EMEA rejects insulin glargine cancer link

Available data do not support a link between insulin glargine (Lantus) and an increased risk of developing cancer, the European Medicines Agency (EMEA) has concluded.

The EMEA investigated the possibility of a link between insulin glargine use and cancer risk after three studies highlighted safety concerns.

Following a review of the data, the agency's Committee for Medicinal Products for Human Use (CHMP) said: ‘The available data does not provide a cause for concern and that changes to the prescribing advice are therefore not necessary.'

The committee said that methodological limitations meant that the studies were inconclusive and did not allow a relationship between insulin glargine and cancer to be confirmed or excluded.

The committee has asked Sanofi-Aventis, Lantus's licence-holder, to develop a strategy for conducting further research into the product's safety profile.


More news from 27 July

BMA guidance on fees for non-NHS work
Half of practices given go-ahead to upload summary care records
DoH primary care czar visits award-winning practice
RCN ends opposition to assisted suicide

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins


Already registered?

Sign in

Before commenting please read our rules for commenting on articles.

If you see a comment you find offensive, you can flag it as inappropriate. In the top right-hand corner of an individual comment, you will see 'flag as inappropriate'. Clicking this prompts us to review the comment. For further information see our rules for commenting on articles.

comments powered by Disqus